QTX-2101 + ATRA Clinical Trials (2026): 1 Studies for Acute Promyelocytic Leukaemia & Acute Promyelocytic Leukemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 QTX-2101 + ATRA clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Acute Promyelocytic Leukaemia & Acute Promyelocytic Leukemia) and 150 total planned enrollment. 1 Phase 3 QTX-2101 + ATRA trial are listed. 1 QTX-2101 + ATRA clinical trial is actively recruiting at 6 U.S. sites across 4 states. Most recent activity: NCT07504458 (Dec 2030).
Where to Participate: All QTX-2101 + ATRA Trial Sites in the U.S. (6 sites across 4 states)
Every actively recruiting QTX-2101 + ATRAtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Quetzal Site 1 | Duarte91010 | NCT07504458 | Map |
| CA | Quetzal Site 5 | Stanford94305 | NCT07504458 | Map |
| NY | Quetzal Site 4 | Buffalo14203 | NCT07504458 | Map |
| NY | Quetzal Site 2 | The Bronx10467 | NCT07504458 | Map |
| TX | Quetzal Site 6 | Houston77030 | NCT07504458 | Map |
| VA | Quetzal Site 3 | Charlottesville22908 | NCT07504458 | Map |
QTX-2101 + ATRA clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P3 | 1 | 1 |
Recruiting QTX-2101 + ATRA clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07504458 | QUATRO-APLPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | P3 | Acute Promyelocytic Leukemia (APL) | 150 | Jun 2026 |
QTX-2101 + ATRA pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| QUATRO-APL | NCT07504458 | P3 | recruiting | Acute Promyelocytic Leukemia (APL) | 150 | — |
All QTX-2101 + ATRA trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07504458 | QUATRO-APL | Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | P3 | recruiting | 150 | Quetzal Therapeutics | Jun 2026 |
QTX-2101 + ATRA clinical trials: frequently asked questions
- How many QTX-2101 + ATRA clinical trials are there?
- 1 QTX-2101 + ATRA clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are QTX-2101 + ATRA clinical trials recruiting in 2026?
- Yes — 1 QTX-2101 + ATRA trial is actively recruiting in 2026, with 6 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is QTX-2101 + ATRA being studied for?
- QTX-2101 + ATRA is being studied for Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia, Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA. The trials are grouped by indication on this page.
- What phase is QTX-2101 + ATRA in?
- QTX-2101 + ATRA clinical trials span 1 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors QTX-2101 + ATRA clinical trials?
- The lead sponsor across the most QTX-2101 + ATRA trials is Quetzal Therapeutics. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming QTX-2101 + ATRAas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: